智通财经APP讯，东方财富(300059.SZ)发布股东询价转让计划书，本次拟参与询价转让的股东为陆丽丽 女士、沈友根先生，出让方拟转让股份总数为2.378亿股，占公司总股本的比例为1.50%。 ...

格隆汇9月30日丨东方财富(300059.SZ)公布，本次拟参与询价转让的股东为陆丽丽女士、沈友根先生； 出让方拟转让股份总数为237,800,000股，占东方财富信息股份有限公司总股本的比例为1.50%。 ...

人民财讯9月30日电，东方财富（300059）9月30日公告，股东陆丽丽、沈友根计划通过询价转让方式， 转让公司股份2.38亿股，占公司总股本的比例为1.50%。 ...

格隆汇9月30日｜东方财富公告，股东陆丽丽和沈友根计划通过询价方式转让其持有的2.38亿股，占公 司总股本的1.5%。本次股份转让不通过集中竞价或大宗交易进行，受让方在受让后6个月内不得转让。 出让方所持股份已解除限售，权属清晰，无限制或禁止转让情形。陆丽丽计划转让2.07亿股，占其持股 比例的56.42%，沈友根计划转让3080.65万股，占其持股比例的100%。本次询价转让的受让方为具备定 价能力和风险承受能力的机构投资者，转让价格下限为不低于前20个交易日股票交易均价的70%。 ...

| 拟参与转让股东的名称 | 持股数量（股） | 占公司总股本比例 | | --- | --- | --- | | 陆丽丽 | 366,869,672 | 2.32% | | 沈友根 | 30,806,534 | 0.19% | 注：公司总股本为15,804,037,675股。 证券代码：300059 证券简称：东方财富 公告编号：2025-071 东方财富信息股份有限公司 股东询价转让计划书 股东陆丽丽、沈友根保证向东方财富信息股份有限公司提供的信息内容不存在任何虚 假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： 一、拟参与转让的股东情况 （一）出让方的名称、持股数量、持股比例 出让方委托中国国际金融股份有限公司（以下简称"中金公司"）组织实施 东方财富首发前股东询价转让（以下简称"本次询价转让"）。截至2025年9月 30日，出让方所持首发前股份的数量、占公司总股本比例情况如下： （二）关于出让方是否为东方财富控股股东、实际控制人、持股5%以上的股 东、董事、监事及高级管理人员 本次询价转让 ...

中国国际金融股份有限公司 关于东方财富信息股份有限公司 股东向特定机构投资者询价转让股份 相关资格的核查意见 中国国际金融股份有限公司（以下简称"中金公司"）受东方财富信息股份有限 公司（以下简称"东方财富"）股东沈友根、陆丽丽（以下合称"出让方"）委托， 组织实施本次东方财富股东向特定机构投资者询价转让（以下简称"本次询价转 让"）。 根据《上市公司股东减持股份管理暂行办法》《深圳证券交易所创业板股票上市 规则（2025 年修订）》《深圳证券交易所上市公司自律监管指引第 18 号——股东及 董事、高级管理人员减持股份（2025 年修订）》《深圳证券交易所上市公司自律监管 指引第 16 号——创业板上市公司股东询价和配售方式转让股份（2025 年修订）》 （以下简称"《指引第 16 号》"）等相关规定，中金公司对参与本次询价出让方的相 关资格进行了核查。 本次询价转让的委托情况、出让方相关资格的核查情况及核查意见如下： 一、本次询价转让的委托 中金公司已收到出让方关于本次询价转让的委托，委托中金公司组织实施本次询 价转让。 1 二、关于参与本次询价转让股东相关资格的核查情况 （一）核查过程 根据相关法规要求， ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

沪指9月30日上涨0.52%，申万所属行业中，今日上涨的有19个，涨幅居前的行业为有色金属、国防军 工，涨幅分别为3.22%、2.59%。跌幅居前的行业为通信、非银金融，跌幅分别为1.83%、1.14%。非银 金融行业位居今日跌幅榜第二。 资金面上看，两市主力资金全天净流出323.03亿元，今日有4个行业主力资金净流入，国防军工行业主 力资金净流入规模居首，该行业今日上涨2.59%，全天净流入资金20.78亿元，其次是有色金属行业，日 涨幅为3.22%，净流入资金为19.84亿元。 主力资金净流出的行业有27个，非银金融行业主力资金净流出规模居首，全天净流出资金114.05亿元， 其次是通信行业，净流出资金为59.36亿元，净流出资金较多的还有机械设备、银行、电力设备等行 业。 | 代码 | 简称 | 今日涨跌幅（%） | 今日换手率（%） | 主力资金流量（万元） | | --- | --- | --- | --- | --- | | 300059 | 东方财富 | -1.67 | 4.28 | -157354.35 | | 601211 | 国泰海通 | -1.10 | 1.73 | -127595.94 ...

Summary of Key Points Core Viewpoint - On September 30, the total trading volume of the Shanghai and Shenzhen stock markets reached 2.18 trillion yuan, indicating an increase of approximately 199.5 billion yuan compared to the previous trading day [1] Trading Volume Details - The trading volume in the Shanghai market was 973.27 billion yuan, while the Shenzhen market recorded 1.21 trillion yuan [1] - New Yi Sheng topped the trading volume with 18.595 billion yuan, followed by Zhongji Xuchuang, Dongfang Caifu, Yangguang Dianyuan, and Lixun Precision with trading volumes of 16.248 billion yuan, 15.563 billion yuan, 15.197 billion yuan, and 14.884 billion yuan respectively [1]

Group 1 - The three major indices experienced a decline, with the brokerage sector falling, as evidenced by the brokerage ETF fund (515010) dropping by 0.96% as of 14:05 on September 30 [3] - In September, the brokerage ETF fund (515010) saw net inflows of funds on 17 out of 21 trading days, totaling 360 million yuan, reaching a new high of 1.786 billion yuan as of September 29 [3] - The brokerage ETF fund (515010) tracks the securities company index (code 399975), with the top ten constituent stocks accounting for 60.56% of the weight, including major brokerages like CITIC Securities and Huatai Securities, benefiting directly from the recovery of the A-share market [3] Group 2 - The financial technology ETF Huaxia (516100) closely tracks the CSI Financial Technology Theme Index, covering software development, internet finance, and the digital currency industry chain, potentially benefiting from both market recovery and AI-related catalysts [3] - The management and custody fee rate for the brokerage ETF fund (515010) is the lowest in the sector at a combined rate of 0.2%, facilitating lower-cost investments in the brokerage sector [3]